Published in Nature on February 25, 1988
Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci U S A (1989) 6.32
Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med (1992) 4.11
Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med (1992) 3.75
Human herpesviruses: a consideration of the latent state. Microbiol Rev (1989) 3.15
Influence of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus. J Virol (1989) 2.86
An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3). J Exp Med (1990) 2.44
Exclusive expression of Epstein-Barr virus nuclear antigen 1 in Burkitt lymphoma arises from a third promoter, distinct from the promoters used in latently infected lymphocytes. Proc Natl Acad Sci U S A (1991) 2.40
Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins. J Virol (1989) 2.23
An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease. J Exp Med (1994) 2.02
Immune regulation in Epstein-Barr virus-associated diseases. Microbiol Rev (1995) 1.90
Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci U S A (1999) 1.82
Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol (2003) 1.80
An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformants. J Virol (1990) 1.79
Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses. Proc Natl Acad Sci U S A (1990) 1.74
HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol (1993) 1.58
T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. J Exp Med (1995) 1.56
Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J Exp Med (2004) 1.45
Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes. Clin Exp Immunol (1991) 1.41
Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide. J Exp Med (1993) 1.38
Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP. J Virol (1988) 1.37
Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T cells. Immunology (1991) 1.30
Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma. Proc Natl Acad Sci U S A (1992) 1.28
Unusually high frequency of Epstein-Barr virus genetic variants in Papua New Guinea that can escape cytotoxic T-cell recognition: implications for virus evolution. J Virol (1996) 1.27
Evolutionary dynamics of genetic variation in Epstein-Barr virus isolates of diverse geographical origins: evidence for immune pressure-independent genetic drift. J Virol (1997) 1.25
Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies. Proc Natl Acad Sci U S A (1991) 1.20
Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. J Immunother Emphasis Tumor Immunol (1994) 1.16
Development of Epstein-Barr virus-specific memory T cell receptor clonotypes in acute infectious mononucleosis. J Exp Med (1996) 1.15
Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res Ther (2004) 1.14
Correlation of the expression of Epstein-Barr virus latent membrane protein and in situ hybridization with biotinylated BamHI-W probes in Hodgkin's disease. Am J Pathol (1992) 1.11
T cell-T cell killing is induced by specific epitopes: evidence for an apoptotic mechanism. J Exp Med (1991) 1.08
Identification of a glucocorticoid-responsive element in Epstein-Barr virus. J Virol (1990) 1.05
The immunology of Epstein-Barr virus infection. Philos Trans R Soc Lond B Biol Sci (2001) 1.04
Identification of a cytotoxic T-lymphocyte response to the novel BARF0 protein of Epstein-Barr virus: a critical role for antigen expression. J Virol (1998) 1.03
MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells. Proc Natl Acad Sci U S A (2002) 1.01
Cytotoxic T-lymphocyte responses to a polymorphic Epstein-Barr virus epitope identify healthy carriers with coresident viral strains. J Virol (2000) 1.00
Identification of a naturally occurring recombinant Epstein-Barr virus isolate from New Guinea that encodes both type 1 and type 2 nuclear antigen sequences. J Virol (1996) 0.99
Host cell-dependent regulation of growth transformation-associated Epstein-Barr virus antigens in somatic cell hybrids. J Virol (1989) 0.96
Epstein-Barr virus and the lacrimal gland pathology of Sjögren's syndrome. Am J Pathol (1993) 0.95
Hierarchy of Epstein-Barr virus-specific cytotoxic T-cell responses in individuals carrying different subtypes of an HLA allele: implications for epitope-based antiviral vaccines. J Virol (1997) 0.90
Identification of type B-specific and cross-reactive cytotoxic T-lymphocyte responses to Epstein-Barr virus. J Virol (1996) 0.88
Epstein-Barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer (2016) 0.88
Selection pressure-driven evolution of the Epstein-Barr virus-encoded oncogene LMP1 in virus isolates from Southeast Asia. J Virol (2004) 0.86
CD8+ T-cell recognition of human cytomegalovirus latency-associated determinant pUL138. J Gen Virol (2010) 0.84
A recombinant adenovirus expressing an Epstein-Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory in vitro. J Virol (1996) 0.83
Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis? Surg Today (2015) 0.83
Failure of Epstein-Barr virus-specific cytotoxic T lymphocytes to lyse B cells transformed with the B95-8 strain is mapped to an epitope that associates with the HLA-B8 antigen. Clin Exp Immunol (1992) 0.82
Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens. Cancer Immunol Res (2016) 0.79
Conservation of Epstein-Barr virus cytotoxic T-cell epitopes in posttransplant lymphomas: implications for immune therapy. Am J Pathol (2002) 0.78
Epstein-Barr virus (EBV) antigens processed and presented by B cells, B blasts, and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation. J Virol (1990) 0.78
Cytotoxic T-lymphocyte clones specific for an immunodominant epitope display discerning antagonistic response to naturally occurring Epstein-Barr virus variants. J Virol (1996) 0.77
Analysis of the tumorigenic potential of common marmoset lymphoblastoid cells expressing a constitutively activated c-myc gene. Br J Cancer (1993) 0.76
Clonal Epstein-Barr virus genome in T-cell-rich lymphomas of B or probable B lineage. Am J Pathol (1992) 0.75
Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. Nat Med (1998) 4.04
Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med (1992) 3.75
Search for a resonance decaying into WZ boson pairs in pp collisions. Phys Rev Lett (2010) 2.83
Long-term T-cell-mediated immunity to Epstein-Barr virus. Cancer Res (1981) 2.74
Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus. J Exp Med (1994) 2.47
An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3). J Exp Med (1990) 2.44
Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu Rev Microbiol (2000) 2.17
HLA-DR-antigen-associated restriction of EBV-specific cytotoxic T-cell colonies. Int J Cancer (1984) 2.14
Immune regulation in Epstein-Barr virus-associated diseases. Microbiol Rev (1995) 1.90
A precision measurement of the mass of the top quark. Nature (2004) 1.87
Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci U S A (1999) 1.82
An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformants. J Virol (1990) 1.79
Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis. J Neurol Neurosurg Psychiatry (2008) 1.77
Category specific access dysphasia. Brain (1983) 1.77
Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses. Proc Natl Acad Sci U S A (1990) 1.74
Purification of a mycobacterial adhesin for fibronectin. Infect Immun (1993) 1.63
Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol (1995) 1.62
HLA antigen-related restriction of T lymphocyte cytotoxicity to Epstein-Barr virus. Proc Natl Acad Sci U S A (1980) 1.60
New type B isolates of Epstein-Barr virus from Burkitt's lymphoma and from normal individuals in endemic areas. J Gen Virol (1987) 1.58
HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading. Immunity (1998) 1.58
Prevention of incisional hernia after aortic aneurysm repair. Eur J Vasc Endovasc Surg (2003) 1.57
T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. J Exp Med (1995) 1.56
Measurement of the forward-backward charge asymmetry in top-quark pair production. Phys Rev Lett (2008) 1.53
Measurement of the W boson mass with the D0 detector. Phys Rev Lett (2012) 1.46
The effect of esmolol pretreatment on the incidence of regional wall motion abnormalities during electroconvulsive therapy. Anesth Analg (1996) 1.45
Vitamin D nutrient intake for all life stages. Ir Med J (2011) 1.45
Adverse events temporally associated with immunizing agents--1989 report. Can Dis Wkly Rep (1991) 1.45
Partial purification of the Epstein-Barr virus nuclear antigen(s). J Biol Chem (1983) 1.44
Frontal lesions and sustained attention. Neuropsychologia (1987) 1.43
An upper limit on the stochastic gravitational-wave background of cosmological origin. Nature (2009) 1.42
Allogeneic stimulation modulates the in vitro response of T cells to transplantation antigen. Nature (1974) 1.37
Expression of Epstein-Barr virus nuclear antigens 3, 4, and 6 are altered in cell lines containing B-type virus. Virology (1989) 1.35
Class I processing-defective Burkitt's lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs. J Immunol (1997) 1.34
Age and sex effects in the EEG: development of the normal child. Clin Neurophysiol (2001) 1.34
Adverse events temporally associated with immunizing agents--1987 report. Can Dis Wkly Rep (1989) 1.33
Identification of multiple Epstein-Barr virus-induced nuclear antigens with sera from patients with rheumatoid arthritis. J Virol (1984) 1.32
Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T cells. Immunology (1991) 1.30
Identification of a novel protein encoded by the BamHI A region of the Epstein-Barr virus. J Virol (1997) 1.28
Quantitative and qualitative influences of tapasin on the class I peptide repertoire. J Immunol (2001) 1.27
Unusually high frequency of Epstein-Barr virus genetic variants in Papua New Guinea that can escape cytotoxic T-cell recognition: implications for virus evolution. J Virol (1996) 1.27
Evolutionary dynamics of genetic variation in Epstein-Barr virus isolates of diverse geographical origins: evidence for immune pressure-independent genetic drift. J Virol (1997) 1.25
Evidence for two classes of chromatin-associated Epstein-Barr virus-determined nuclear antigen. J Virol (1982) 1.25
Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies. Proc Natl Acad Sci U S A (1991) 1.20
A comparative study of heavy metal concentration and distribution in deposited street dusts in a large and a small urban area: Birmingham and Coventry, West Midlands, UK. Environ Int (2003) 1.18
Acquisition of post-morbid vocabulary and semantic facts in the absence of episodic memory. Brain (1998) 1.18
Ipsilateral cortical projections to areas 3a, 3b, and 4 in the macaque monkey. J Comp Neurol (1993) 1.18
Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. Blood (2001) 1.18
A two-route model of speech production. Evidence from aphasia. Brain (1984) 1.18
T lymphocytes in infectious mononucleosis. I. T cell death in vitro. Clin Exp Immunol (1985) 1.17
Immune surveillance against Epstein-Barr virus. Semin Immunol (1992) 1.16
X-Linked agammaglobulinemia patients are not infected with Epstein-Barr virus: implications for the biology of the virus. J Virol (1999) 1.15
Development of Epstein-Barr virus-specific memory T cell receptor clonotypes in acute infectious mononucleosis. J Exp Med (1996) 1.15
Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. Proc Natl Acad Sci U S A (1995) 1.14
A novel approach to antigen-specific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class I/peptide complex. Immunity (2001) 1.14
A comparison of Epstein-Barr virus-specific T-cell immunity in malaria-endemic and -nonendemic regions of Papua New Guinea. Int J Cancer (1983) 1.13
Upper limits on a stochastic background of gravitational waves. Phys Rev Lett (2005) 1.11
Adverse events temporally associated with immunizing agents--1988 report. Can Dis Wkly Rep (1990) 1.10
Category specificity in an agrammatic patient: the relative impairment of verb retrieval and comprehension. Neuropsychologia (1985) 1.10
Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells. Cancer Res (1998) 1.10
Measurement of the electron charge asymmetry in pp[over ]-->W+X-->enu+X events at sqrt[s]=1.96 TeV. Phys Rev Lett (2008) 1.09
Longitudinal dynamics of antigen-specific CD8+ cytotoxic T lymphocytes following primary Epstein-Barr virus infection. Blood (2001) 1.09
T cell-T cell killing is induced by specific epitopes: evidence for an apoptotic mechanism. J Exp Med (1991) 1.08
Evidence for a particle produced in association with weak bosons and decaying to a bottom-antibottom quark pair in higgs boson searches at the tevatron. Phys Rev Lett (2012) 1.08
In situ hybridization to show sequential expression of osteoblast gene markers during bone formation in vivo. J Bone Miner Res (1994) 1.08
Heterogeneity within the Epstein-Barr virus nuclear antigen 2 gene in different strains of Epstein-Barr virus. J Gen Virol (1994) 1.08
Induction of Epstein-Barr virus nuclear antigens. J Virol (1986) 1.06
Determination of the width of the top quark. Phys Rev Lett (2011) 1.05
Monoamine oxidase inhibitors: should they be discontinued preoperatively? Anesth Analg (1985) 1.05
Subtypes of Epstein-Barr virus in human immunodeficiency virus-associated non-Hodgkin lymphoma. Blood (1991) 1.04
The immunology of Epstein-Barr virus infection. Philos Trans R Soc Lond B Biol Sci (2001) 1.04
Search for large extra dimensions via single photon plus missing energy final states at sqrt s = 1.96 TeV. Phys Rev Lett (2008) 1.04
Identification of a cytotoxic T-lymphocyte response to the novel BARF0 protein of Epstein-Barr virus: a critical role for antigen expression. J Virol (1998) 1.03
Epstein-Barr nuclear antigen-3 and -4 interact with RBP-2N, a major isoform of RBP-J kappa in B lymphocytes. Virology (1996) 1.02
Search for doubly charged Higgs boson pair production in pp¯ collisions at √s=1.96 TeV. Phys Rev Lett (2012) 1.02
Age and sex effects in the EEG: differences in two subtypes of attention-deficit/hyperactivity disorder. Clin Neurophysiol (2001) 1.01
Electroencephalogram differences in two subtypes of attention-deficit/hyperactivity disorder. Psychophysiology (2001) 1.01
The price you pay for the drug not taken. Bus Health (1998) 1.01
Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing. Int Immunol (1997) 1.00
Identification of a naturally occurring recombinant Epstein-Barr virus isolate from New Guinea that encodes both type 1 and type 2 nuclear antigen sequences. J Virol (1996) 0.99
Targeting of EBNA1 for rapid intracellular degradation overrides the inhibitory effects of the Gly-Ala repeat domain and restores CD8+ T cell recognition. J Biol Chem (2001) 0.99
Distinct functions of tapasin revealed by polymorphism in MHC class I peptide loading. J Immunol (2000) 0.99